Literature DB >> 30317851

Synchronous Hepatocellular Carcinoma and Cholangiocellular Carcinoma on 18F-FDG PET/CT

Ezgi Başak Erdoğan1, Hacı Mehmet Türk2, Ertuğrul Tekçe3, Mehmet Aydın1.   

Abstract

A 43-year-old male patient presented with a mass lesion on the right liver lobe, segment 5, in radiological imaging and elevated alpha-fetoprotein levels (323 ng/mL) compatible with hepatocellular carcinoma (HCC). Positron emission tomography/computed tomography (PET/CT) images showed background level 18F-FDG uptake in the mass lesion. In addition, a secondary focus of increased 18F-FDG uptake was detected on the left liver lobe, segment 2, approximately 1,5 cm in diameter. Histopathological examination revealed HCC in the larger mass lesion with a lower 18F-FDG uptake, and cholangiocellular carcinoma in the smaller mass lesion with a higher 18F-FDG uptake. To our knowledge, this is the first case report of two histopathologically different primary malignant liver tumors in two distinct segments of the liver detected by PET/CT.

Entities:  

Keywords:  Synchronous tumors; hepatocellular carcinoma; cholangiocellular carcinoma; 18F-FDG PET/CT

Year:  2018        PMID: 30317851      PMCID: PMC6191735          DOI: 10.4274/mirt.93723

Source DB:  PubMed          Journal:  Mol Imaging Radionucl Ther        ISSN: 2146-1414


  7 in total

1.  COMPARATIVE BIOCHEMISTRY OF HEPATOMAS. III. CARBOHYDRATE ENZYMES IN LIVER TUMORS OF DIFFERENT GROWTH RATES.

Authors:  G WEBER; H P MORRIS
Journal:  Cancer Res       Date:  1963-08       Impact factor: 12.701

2.  Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake.

Authors:  Jong Doo Lee; Woo Ick Yang; Young Nyun Park; Kyung Sik Kim; Jin Sub Choi; Mijin Yun; Dooheun Ko; Tae-Sung Kim; Arthur E H Cho; Hye Mi Kim; Kwang-Hyub Han; Seung-Soon Im; Yong-Ho Ahn; Chang Woon Choi; Jeon Han Park
Journal:  J Nucl Med       Date:  2005-10       Impact factor: 10.057

3.  FDG PET in the diagnosis of hilar cholangiocarcinoma.

Authors:  A Fritscher-Ravens; K H Bohuslavizki; D C Broering; L Jenicke; H Schäfer; R Buchert; X Rogiers; M Clausen
Journal:  Nucl Med Commun       Date:  2001-12       Impact factor: 1.690

4.  Synchronous development of HCC and CCC in the same subsegment of the liver in a patient with type C liver cirrhosis.

Authors:  Takuya Watanabe; Jun Sakata; Takashi Ishikawa; Yoshio Shirai; Takeyasu Suda; Haruka Hirono; Katsuhiko Hasegawa; Kenji Soga; Koichi Shibasaki; Yukifumi Saito; Hajime Umezu
Journal:  World J Hepatol       Date:  2009-10-31

5.  Role of 18F-FDG PET/CT Imaging in Intrahepatic Cholangiocarcinoma.

Authors:  Lei Jiang; Hui Tan; Cedric M Panje; Haojun Yu; Yan Xiu; Hongcheng Shi
Journal:  Clin Nucl Med       Date:  2016-01       Impact factor: 7.794

Review 6.  Cholangiolocellular carcinoma containing hepatocellular carcinoma and cholangiocellular carcinoma, extremely rare tumor of the liver:a case report.

Authors:  Mami Kanamoto; Tomoharu Yoshizumi; Toru Ikegami; Satoru Imura; Yuji Morine; Tetsuya Ikemoto; Nobuya Sano; Mitsuo Shimada
Journal:  J Med Invest       Date:  2008-02

Review 7.  Double primary hepatic cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) originating from hepatic progenitor cell: a case report and review of the literature.

Authors:  Junwen Hu; Rongfa Yuan; Changwen Huang; Jianghua Shao; Shubing Zou; Kai Wang
Journal:  World J Surg Oncol       Date:  2016-08-17       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.